Janssen Biologics

For more than 25 years, Janssen Biologics has been a leader in the field of biomedicines. Through the dynamic science of biotechnology, we continue to seek innovative ways to treat cancer, infectious diseases, cardiovascular and metabolic diseases, and immune-mediated inflammatory disorders (I.M.I.D.s), such as rheumatoid arthritis and psoriasis. Our work has revolutionized the science of immunology. We pioneered monoclonal antibody technology, a cutting-edge approach that launched a new generation of products to treat immune-related diseases.Janssen Biologics is an wholly owned subsidiary of Johnson & Johnson.